Colonoscopy, cancer prevention, and the new arithmetic of benefit
Mené auprès de 84 583 personnes âgées de 55 à 64 ans (durée de suivi : 13 ans), cet essai international (Norvège, Pologne et Suède) évalue l'effet à long terme d'une coloscopie de dépistage sur l'incidence du cancer colorectal et la mortalité
For more than two decades, colonoscopy has been promoted as the gold standard for colorectal cancer screening. Policy makers and professional societies have largely accepted observational data and modelling estimates that suggest that colonoscopy cuts colorectal cancer incidence and mortality by at least 50%.1 Against this backdrop of strong belief but insufficient randomised evidence, the NordICC randomised clinical trial of colonoscopy screening versus usual care for the primary endpoints of colorectal cancer incidence and mortality has been uniquely important.2 The study's 13-year results compel a recalibration of what colonoscopy can—and cannot—achieve at the population level.
The Lancet , commentaire, 2026